scholarly journals Carboxypeptidase A1 (CPA1) immunohistochemistry is highly sensitive and specific for acinar cell carcinoma (ACC) of the pancreas

2021 ◽  
Vol 156 (Supplement_1) ◽  
pp. S106-S107
Author(s):  
R Uhlig ◽  
T Clauditz

Abstract Introduction/Objective Introduction: Carboxypeptidase A1 (CPA1) is a zinc metalloprotease which is produced in pancreatic acinar cells and plays a role in cleaving C-terminal branched-chain and aromatic amino acids from dietary proteins. This study assessed the utility of immunohistochemical CPA1 staining for diagnosing pancreatic acinar cell carcinoma. Methods/Case Report Methods: A total of 15,680 tumor samples from 132 different tumor types and subtypes as well as 8 samples each of 76 different normal tissue types were analyzed by immunohistochemistry in a tissue microarray format. Results (if a Case Study enter NA) Results: CPA1 was strongly expressed in acinar cells of all normal pancreas samples but not in any other normal tissues. CPA1 immunostaining was detected in 100% of 11 pancreatic acinar cell carcinomas and one mixed acinar endocrine carcinoma (MAEC), but absent in 449 pancreatic ductal adenocarcinomas, 75 adenocarcinomas of the ampulla of Vater, and 11,739 other evaluable cancers from 128 different tumor entities. A weak to moderate diffuse staining of epithelial and stromal cells of cancer tissues immediately adjacent to non-neoplastic pancreatic acinar cells often occurred and was considered to be caused by diffusion of the highly abundant CPA1 from normal acinar cells that may have suffered some autolytic cell damage. Conclusion Our data show that CPA1 is a highly sensitive and largely specific marker for normal and neoplastic pancreatic acinar cells. CPA1 immunohistochemistry greatly facilitates the otherwise often difficult diagnosis of pancreatic acinar cell carcinoma.

2008 ◽  
Vol 454 (2) ◽  
pp. 133-142 ◽  
Author(s):  
Stefano La Rosa ◽  
Francesca Franzi ◽  
Silvia Marchet ◽  
Giovanna Finzi ◽  
Moira Clerici ◽  
...  

2007 ◽  
Vol 18 (2) ◽  
pp. 95-102 ◽  
Author(s):  
György Illyés ◽  
Andrea Luczay ◽  
Gábor Benyó ◽  
Attila Kálmán ◽  
Katalin Borka ◽  
...  

2007 ◽  
Vol 106 (8) ◽  
pp. 669-672 ◽  
Author(s):  
Yang-Chao Lin ◽  
Po-Huang Lee ◽  
Yu-Tung Yao ◽  
Jong-Kai Hsiao ◽  
Jin-Chuan Sheu ◽  
...  

1996 ◽  
Vol 3 (1) ◽  
pp. 71-73 ◽  
Author(s):  
Takashi Ohsato ◽  
Ryuichi Mibu ◽  
Eishi Nagai ◽  
Hiroshi Satoh ◽  
Mitsuo Iida ◽  
...  

Suizo ◽  
2019 ◽  
Vol 34 (5) ◽  
pp. 270-278
Author(s):  
Taro MASHIKO ◽  
Kohei TAJIMA ◽  
Naoki YAZAWA ◽  
Yoshihito MASUOKA ◽  
Toshio NAKAGOHRI

2021 ◽  
Author(s):  
Jianying Xu ◽  
Wenlong Guan ◽  
Shixun Lu ◽  
Xiaoli Wei ◽  
Wenjie Shi ◽  
...  

Abstract Background: Pancreatic acinar cell carcinoma (PACC) is rare and its appropriate treatment remains unknown dued to limited and selection-biased dataMethods: The data on clinicopathologic characteristics, molecular alteration, treatment and survival of patients diagnosed as PACC in Sun Yat-sen university cancer center from 2005 to 2020 were collected. We explored the optimal treatment by co-analyzing our results and published literatures.Results: 22 PACC patients were enrolled. 8/17 non-metastatic patients received adjuvant chemotherapy. The patients receiving fluoropyrimidine-based regimen (n=3) had better mDFS than those with gemcitabine-based regimen (n=5) (unreached vs. 27 months). 8 metastatic patients received 1st-line chemotherapy. 4/5 patients with FOLFIRINOX regimen achieved partial response (PR) and 3 patients with AG (albumin paclitaxel+gemcitabine) regimen got progressive disease (PD). 4 patients received 2nd-line chemotherapy. 2 patients with FOLFIRINOX regimen achieved PR while 2 patients with AG regimen got PD. One patient who had responded to 1st-line FOLFIRINOX regimen received Olaparib as maintenance treatment for 5 months with good tolerance. 31 published literatures and a total of 86 cases were included in the co-analysis. Objective response rate of 1st-line fluoropyrimidine-based regimen (n=47) was higher than that of gemcitabine-based regimen (n=39) (59.6% vs.15.3%, P<0.001). 8/11 patients treated with FOLFIRINOX regimen achieved PR. Conclusions: The benefit of adjuvant chemotherapy remained unclear; however, fluoropyrimidine-based chemotherapy deserves attention. For metastatic patients, fluorouracil-based regimen such as FOLFIRINOX is preferred, and maintenance treatment of PARP inhibitors after effective platinum-containing treatment for BRAC mutation patients is worthy of exploration.


2018 ◽  
Vol 57 (24) ◽  
pp. 3529-3535 ◽  
Author(s):  
Naoki Yoshida ◽  
Atsushi Kanno ◽  
Atsushi Masamune ◽  
Tatsuhide Nabeshima ◽  
Seiji Hongo ◽  
...  

Pathology ◽  
2018 ◽  
Vol 50 (3) ◽  
pp. 345-348 ◽  
Author(s):  
Angela Chou ◽  
Yoomee Kim ◽  
Jaswinder S. Samra ◽  
Marina Pajic ◽  
Anthony J. Gill

Sign in / Sign up

Export Citation Format

Share Document